Allergy & Immunology

Chronic Spontaneous Urticaria

Looking Ahead to ACAAI 2026: The Topics Our Experts Are Excited About

conference reporter by Thomas B. Casale, MD; Sandra M. Gawchik, DO, FAAAAI, FACAAI

Overview

As the Chronic Spontaneous Urticaria community prepares to gather for ACAAI 2026, anticipation is building around the latest developments in treatment, diagnostics, clinical research, and patient care. Ahead of this year’s meeting, we asked our Expert panel to share what they are most eager to follow and the developments they believe could have the greatest impact.

"I am most excited to hear about new strategies for the treatment of chronic spontaneous urticaria. There are many novel therapies that are undergoing clinical trials. I believe that the technological advances in targeted therapy development—including bispecific and trispecific monoclonal antibodies and small molecules capable of inhibiting critical pathways—will provide new and better therapies for patients."

— Thomas B. Casale, MD

"At ACAAI 2026, I am looking forward to hearing about recent research on the phenotypes, endotypes, and comorbidities of chronic spontaneous urticaria. In addition, current and emerging therapies for both chronic spontaneous urticaria and chronic inducible urticaria will be on my radar. As chronic spontaneous urticaria can significantly impact patients' lives, both professionally and personally, it is incredibly important that it is diagnosed promptly. Presentations at ACAAI 2026 will also address this important issue, helping to unmask the masqueraders of CSU, which, when missed, can often result in delays in diagnosis of 2 years or greater."

— Sandra M. Gawchik, DO, FAAAAI, FACAAI

Stay tuned for continued coverage from ACAAI 2026, where our Conference Reporter Expert panel will share key takeaways, emerging data, and expert perspectives throughout the meeting as part of our Conference Reporter^® in Chronic Spontaneous Urticaria series.

This information is brought to you by Engage Health Media and is not sponsored, endorsed, or accredited by the American College of Allergy, Asthma & Immunology.

Profile

Thomas B. Casale, MD

Professor of Medicine and Pediatrics
Chief of Clinical and Translational Research
Division of Allergy and Immunology
University of South Florida
Tampa, FL

Profile

Sandra M. Gawchik, DO, FAAAAI, FACAAI

Allergist and Immunologist
Asthma & Allergy Associates
Glen Mills and West Chester, PA
Clinical Associate Professor of Pediatrics
Thomas Jefferson University Hospital
Philadelphia, PA